Accent Therapeutics

Black Diamond Therapeutics

This clinical-stage company develops precision oncology medicines and small molecule therapies for patients with genetically defined cancers.

Scorpion Therapeutics

This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.

Carrick Therapeutics

This biopharmaceutical company develops precision oncology therapies for patients with aggressive cancers, focusing on small molecules and inhibitors for solid tumours.

Acrivon Therapeutics

This biopharmaceutical company develops precision oncology medicines and proteomics-based companion diagnostics for cancer patients.

MyCural Therapeutics

This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.